多発性硬化症(MS)疫学予測

◆英語タイトル:Multiple Sclerosis - Epidemiology Forecast
◆商品コード:DELV803011
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:102
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥357,500見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD6,500 ⇒換算¥715,000見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD9,750 ⇒換算¥1,072,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Multiple Sclerosis – Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Multiple Sclerosis Epidemiology
The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Multiple Sclerosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Multiple Sclerosis Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by Gender [male/female], age group [≤19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years], sub-types [Relapsing Remitting MS, Primary Progressive MS and Progressive relapsing MS] and Expanded disability status scale (EDSS) [0.0-1.5, 2.0-3.5, 4.0-5.5, 6.0-7.5 and 8.0-9.5], thus presenting overall detailed analysis of the patient pool characteristics.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45–49 years in both female and male participants.

Report Scope
• The report covers detailed overview of Multiple Sclerosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Multiple Sclerosis
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender, age-group, sub-types and EDSS score in 7MM

Key strengths
• 10 Year Forecast of Multiple Sclerosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Multiple Sclerosis
• Prevalent Cases according to segmentation: Gender-specific prevalence, age-specific prevalence, sub-type specific prevalence and prevalence based upon EDSS score

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

【レポートの目次】

1. Report Introduction 1
2. Multiple Sclerosis Epidemiology Overview at a Glance 2
2.1. Prevalent Population of Multiple Sclerosis in 2017 2
2.2. Prevalent Population of Multiple Sclerosis in 2027 2
3. Disease Background and Overview: Multiple Sclerosis (MS) 13
3.1. Introduction 13
3.2. Risk Factors 16
3.3. Causes 17
3.4. Symptoms 18
3.5. Pathogenesis 20
3.6. Diagnosis 25
3.7. Expanded Disability Status Scale (EDSS) 29
4. Epidemiology and Patient Population 31
4.1. Key Findings 31
4.2. Population and Forecast Parameters 32
4.3. Prevalent Population of Multiple Sclerosis in 7MM 33
4.4. Prevalent Population of Multiple Sclerosis in 7MM – By Region 34
4.5. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2017) 35
4.6. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2027) 35
5. Epidemiology of Multiple Sclerosis 36
6. United States 36
6.1. Assumptions and Rationale 36
6.2. Prevalent Population of Multiple Sclerosis in United States 39
6.3. Sex-Specific Prevalence of Multiple Sclerosis in United States 40
6.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States 41
6.5. Age-Specific Prevalence of Multiple Sclerosis in United States 42
6.6. Prevalence of Multiple Sclerosis based on EDSS Score in United States 43
7. Germany 44
7.1. Assumptions and Rationale 44
7.2. Prevalent Population of Multiple Sclerosis in Germany 46
7.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany 47
7.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany 48
7.5. Age-Specific Prevalence of Multiple Sclerosis in Germany 49
7.6. Prevalence of Multiple Sclerosis based on EDSS Score in Germany 50
8. France 51
8.1. Assumptions and Rationale 51
8.2. Prevalent Population of Multiple Sclerosis in France 53
8.3. Sex-Specific Prevalence of Multiple Sclerosis in France 54
8.4. Sub-type Specific Prevalence of Multiple Sclerosis in France 55
8.5. Age-Specific Prevalence of Multiple Sclerosis in France 56
8.6. Prevalence of Multiple Sclerosis based on EDSS Score in France 57
9. Italy 58
9.1. Assumptions and Rationale 58
9.2. Prevalent Population of Multiple Sclerosis in Italy 60
9.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy 61
9.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy 62
9.5. Age-Specific Prevalence of Multiple Sclerosis in Italy 63
9.6. Prevalence of Multiple Sclerosis based on EDSS Score in Italy 64
10. Spain 65
10.1. Assumptions and Rationale 65
10.2. Prevalent Population of Multiple Sclerosis in Spain 67
10.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain 68
10.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain 69
10.5. Age-Specific Prevalence of Multiple Sclerosis in France 70
10.6. Prevalence of Multiple Sclerosis based on EDSS Score in Spain 71
11. United Kingdom 72
11.1. Assumptions and Rationale 72
11.2. Prevalent Population of Multiple Sclerosis in United Kingdom 74
11.3. Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom 75
11.4. Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom 76
11.5. Age-Specific Prevalence of Multiple Sclerosis in United Kingdom 77
11.6. Prevalence of Multiple Sclerosis based on EDSS Score in United Kingdom 78
12. Japan 79
12.1. Assumptions and Rationale 79
12.2. Prevalent Population of Multiple Sclerosis in Japan 81
12.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan 82
12.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan 83
12.5. Age-Specific Prevalence of Multiple Sclerosis in Japan 84
12.6. Prevalence of Multiple Sclerosis based on EDSS Score in Japan 85
13. Unmet Needs 97
14. Appendix 98
15. Report Methodology 98
15.1. Sources Used 98
16. Consulting Services 101
17. Disclaimer 102
18. About DelveInsight 102

Table 1: Expanded Disability Status Scale (EDSS) 29
Table 2: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Table 3: Prevalent Population of Multiple Sclerosis in 7MM- By Region (2016-2027) 34
Table 4: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Table 5: Sex-Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Table 6: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
Table 7: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 42
Table 8: Prevalent Population of Multiple Sclerosis based on EDSS Score in United States (2016-2027) 43
Table 9: Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 46
Table 10: Sex-Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 47
Table 11: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 48
Table 12: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 49
Table 13: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027) 50
Table 14: Prevalent Population of Multiple Sclerosis in France (2016-2027) 53
Table 15: Sex-Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 54
Table 16: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 55
Table 17: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 56
Table 18: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027) 57
Table 19: Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 60
Table 20: Sex-Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 61
Table 21: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 62
Table 22: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 63
Table 23: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027) 64
Table 24: Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 67
Table 25: Sex-Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 68
Table 26: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 69
Table 27: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 70
Table 28: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027) 71
Table 29: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 74
Table 30: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 75
Table 31: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 76
Table 32: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 77
Table 33: Prevalent Population of Multiple Sclerosis based on EDSS Score in United Kingdom (2016-2027) 78
Table 34: Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 81
Table 35: Sex-Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 82
Table 36: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan(2016-2027) 83
Table 37: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 84
Table 38: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027) 85


Figure 1: Types of MS 14
Figure 2: Risk factors associated with MS 16
Figure 3: The immunological complexity of the immune/cytokine network in multiple sclerosis 21
Figure 4: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Figure 5: Prevalent Population of Multiple Sclerosis in 7MM- By Region(2016-2027) 34
Figure 6: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
Figure 9: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 42
Figure 10: Prevalent Population of Multiple Sclerosis based on EDSS Score in US (2016-2027) 43
Figure 11: Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 46
Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 47
Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 48
Figure 14: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 49
Figure 15: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027) 50
Figure 16: Prevalent Population of Multiple Sclerosis in France (2016-2027) 53
Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 54
Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 55
Figure 19: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 56
Figure 20: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027) 57
Figure 21: Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 60
Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 61
Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 62
Figure 24: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 63
Figure 25: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027) 64
Figure 26: Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 67
Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 68
Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 69
Figure 29: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 70
Figure 30: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027) 71
Figure 31: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 74
Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 75
Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 76
Figure 34: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 77
Figure 35: Prevalent Population of Multiple Sclerosis based on EDSS Score in UK (2016-2027) 78
Figure 36: Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 81
Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 82
Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 83
Figure 39: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 84
Figure 40: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027) 85


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 多発性硬化症(MS)疫学予測(Multiple Sclerosis - Epidemiology Forecast)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆